Coherus Biosciences (CHRS) PT Raised to $25 at Citi
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.37 +1.48%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
Citi raised its price target on Coherus Biosciences (NASDAQ: CHRS) to $25.00 (from $23.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Designer Brands (DBI) PT Lowered to $6 at UBS
- Coherus to Participate in Upcoming Investor Conferences
- Science Applications (SAIC) PT Raised to $123 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
